BioSpace News Archive

The U.S. National Institutes of Health (NIH) is launching a clinical trial of a combination of Gilead Sciences’ antiviral drug remdesivir (Vitrakvy) and hyperimmune intravenous immunoglobulin (hIVIG).

Since 1990, drug companies’ political committees have largely donated to Republican presidential campaigns. But that trend has noticeably reversed come the 2020 election cycle, according to a new report from the Center for Responsive Politics which shows that approximately 51% of total contributions in 2020 from biopharma organizations are being funneled toward Democrats.

This morning, the pharma giant announced the PENELOPE-B study failed to hit the mark of improved invasive disease-free survival (iDFS).

Supplies of remdesivir are running out across Europe, leading to rationing and reliance on the generic drug, dexamethasone. The UK rationed its supplies of remdesivir Tuesday in the face of rising demands.

It’s been a fairly busy week for biotech initial public offerings (IPOs) with four announcing their list pricing. Here’s a look.

New 50,000-square-foot facility will allow them to expand their services from development and Phase I/II to Phase III and manufacturing.

Despite the change of corporate name, the company said it will maintain its focus on the pursuit of developing novel therapies for solid tumors and blood-related cancers.

It was a moderately busy week for clinical trial news. Here’s a look.

New Lead Interface Designs Serve as Cost-efficient Method for Development of Neurostimulation Devices

Laboratory shakers find use in microbiology, chemistry, molecular biology, biochemistry, clinical diagnostics, and environmental and food sciences.